Viking Therapeutics
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investi...
Latest News
1 day ago · gurufocus.com
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek 2026PR NewswireSAN DIEGO, Nov. 15, 2026VENTURE Analysis Finds 74% of P
3 days ago · fool.com
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028Viking's oral phase 3 obesity trial is key to expanding its addressable market and securing a favorable market share. Peak sales and valuation projections need to be based on risk-adjusted scenarios.
5 days ago · fxempire.com
Viking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55Viking Therapeutics is showing early signs of a bullish reversal, with improving momentum and key support potentially setting up a recovery toward a major consolidation breakout.
8 days ago · prnewswire.com
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026Poster Presentations Highlight Baseline Characteristics from the Phase 3 VANQUISH-2 Trial of Subcutaneous VK2735 and the Impact of VK2735 on Obesity Severity and Cardiometabolic Parameters in the Phase 2 VENTURE Study SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will present two posters highlighting its VK2735 program at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026, in Washington, D.C. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity.
12 days ago · fool.com
Here's the 1 Stock I'd Most Want to Buy If the Market CrashesViking's ongoing phase 3 trials are the key to unlocking value for shareholders. Its lead drug, VK2735, has demonstrated impressive results in a phase 2 trial.
13 days ago · fool.com
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.The weight loss drug market is on track to reach nearly $100 billion by the end of the decade. Viking has a candidate, in two formulations, involved in phase 3 studies.
13 days ago · prnewswire.com
Viking Therapeutics to Participate at Upcoming Investor ConferencesSAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Stifel 2026 Healthcare Conference, Truist 2026 BioPharma Symposium, UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference in November and December. Details of the company's participation are as follows: Stifel 2026 Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings.Conference Dates: November 10-12, 2026Fireside Chat Date/Time: Wednesday, November 11th, 10:40 am – 11:10 am ETLocation: New York, NY Truist 2026 BioPharma Symposium Details: Viking management will participate in investor meetings.Conference Date: November 12, 2026Location: New York, NY UBS Global Biopharma Conference Details: Viking management will participate in a fireside chat and investor meetings.Conference Dates: November 16-17, 2026Fireside Chat Date/Time: Tuesday, November 17th, 10:40 am - 11:10 am ETLocation: London, UK Jefferies Global Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings.Conference Dates: November 16-19, 2026Fireside Chat Date/Time: Wednesday, November 18th, 2:00 pm – 2:25 pm GMTLocation: London, UKWebcast available Piper Sandler 38th Annual Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings.Conference Dates: December 1-3, 2026Fireside Chat Date/Time: Wednesday, December 2nd, 2:00 pm - 2:25 pm ETLocation: New York, NYWebcast available A live webcast of the Jefferies and Piper Sandler fireside chats may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts.
18 days ago · zacks.com
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.
18 days ago · zacks.com
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a BetWhen deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
19 days ago · zacks.com
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical ExpensesViking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VKTX